CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its fourth quarter earnings results after market close on
Tuesday, February 28, 2017. Management will hold a conference call to
review the Company's financial performance starting at 4:30 p.m. ET on
the same day. The conference call will be concurrently webcast. The link
to the webcast will be available on the GenMark Diagnostics, Inc.
website at www.genmarkdx.com
under the investor relations section and will be archived for future
reference. To listen to the conference call, please dial (877) 312-5847
(US/Canada) or (253) 237-1154 (International) and use the conference ID
number 51141106 approximately five minutes prior to the start time.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of automated,
multiplex molecular diagnostic testing systems that detect and measure
DNA and RNA targets to diagnose disease and optimize patient treatment.
Utilizing GenMark's proprietary eSensor® detection
technology, GenMark's eSensor XT-8® system is designed to
support a broad range of molecular diagnostic tests with a compact,
easy-to-use workstation and self-contained, disposable test cartridges.
The eSensor detection technology is also incorporated into GenMark's
sample-to-answer system, ePlex®. For more information, visit www.genmarkdx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005928/en/
GenMark Diagnostics, Inc.
Source: GenMark Diagnostics, Inc.
News Provided by Acquire Media